Clinical trials
Phase 3 Seizures trials in Spain
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
35 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2005 | 2 |
| 2006 | 2 |
| 2007 | 1 |
| 2008 | 1 |
| 2009 | 1 |
| 2010 | 1 |
| 2011 | 1 |
| 2012 | 2 |
| 2013 | 1 |
| 2016 | 3 |
| 2017 | 2 |
| 2018 | 1 |
| 2019 | 1 |
| 2020 | 1 |
| 2021 | 2 |
| 2022 | 4 |
| 2023 | 3 |
| 2024 | 2 |
| 2025 | 4 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 17 |
| Recruiting | 5 |
| Terminated | 5 |
| Active, not recruiting | 4 |
| Enrolling by invitation | 3 |
| Withdrawn | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | 4 |
| Xenon Pharmaceuticals Inc. | 4 |
| GlaxoSmithKline | 3 |
| Longboard Pharmaceuticals | 3 |
| SK Life Science, Inc. | 3 |
| Zogenix International Limited, Inc., a subsidiary of Zogenix, Inc. | 3 |
| Epygenix | 2 |
| Jazz Pharmaceuticals | 2 |
| Novartis Pharmaceuticals | 2 |
| Amzell | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Seizures | 35 |
| Epilepsy | 22 |
| Epilepsies, Myoclonic | 7 |
| Epilepsies, Partial | 7 |
| Lennox Gastaut Syndrome | 5 |
| Brain Diseases | 4 |
| Tuberous Sclerosis | 4 |
| Epilepsy, Tonic-Clonic | 3 |
| Neurodevelopmental Disorders | 3 |
| Spasms, Infantile | 3 |
Trials
Showing 1 to 25 of 35. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.